Grants and Contributions:
Title:
UK Biomanufacturing - 10143578 - NPmsDNA2024 - Development of in vivo targeted non-viral gene therapies
Agreement Number:
1034236
Agreement Value:
$130,700.00
Agreement Date:
Aug 1, 2025 - Mar 31, 2027
Description:
As part of the international consortium project “NPmsDNA2024: Development of in vivo targeted non-viral gene therapies” this project will focus on leveraging Entos’ Fusogenix PLV formulations optimized for delivery of DNA-based genetic medicines to target cell types of the retina to address unmet medical need in rare ophthalmological diseases, including Stargardt Disease. The project will evaluate novel DNA based genetic medicines, encapsulated with Entos’ Fusogenix PLV formulations, for enhanced bioactivity, durable transgene expression and optimal tolerability in small animal models.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Edmonton, Alberta, CA T5J 4P6
Reference Number:
172-2025-2026-Q2-1034236
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
816561112
Recipient Type:
For-profit organization
Recipient's Legal Name:
Entos Pharmaceuticals Inc.
Federal Riding Name:
Edmonton Centre
Federal Riding Number:
48014
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710